Everything that happened today

on

Article Digest Summary

Event
subject: Wife filled husband's phone with child porn in attempt to get custody of children, Oklahoma police say
Event
subject: Japanese researcher suggests ties between omicron variant and severe hepatitis in children
Event
subject: Want to prevent pandemics? Stop spillovers | Decision-makers discussing landmark agreements on health and biodiversity must include four actions to reduce the risk of animals and people exchanging viruses
Event
subject: Church linked to San Jose kidnapping also tied to apparent exorcism death of 3-year-old girl
Event
subject: Prosecutor on his honeymoon is gunned down by hit men on jet skis
Event
subject: Meatpackers hyped 'baseless' shortage to keep plants open amid covid
Event
subject: Finland's leaders call for NATO membership 'without delay'
Event
subject: The AP Interview: US 'vulnerable' to COVID without new shots
Event
subject: Generic drugmakers to sell Pfizer's Paxlovid for $25 or less in low-income countries
Event
subject: How misinformation and the partisan divide drove a surge in U.S. COVID deaths
Event
subject: Mask Mandate Reinstated for San Jose City Workers
Event
subject: Louisiana State Troopers Charged in Beating of Black Man
Event
subject: Police search for gunman who shot three Korean women at Texas hair salon
Event
subject: Spain to ease abortion limits for over-16s and allow menstrual leave
Event
subject: N. Korea says over 18,000 patients confirmed with COVID-19 on Thursday | Yonhap News Agency
Event
subject: Russia demands formal Polish apology for Warsaw anti-war protest
Event
subject: California Pentecostal Church Confirms 3-year-old Girl Died during Attempted Exorcism
Event
subject: Police: Woman fatally shoots her 2 kids, self in Oregon
Event
subject: RCMP officers privately warned their loved ones that a killer was on the loose, but didn't warn the broader public
Event
subject: N. Korea reports 6 deaths after admitting COVID-19 outbreak
Event
subject: UK finds 176 kids with mystery hepatitis
Event
subject: LA Resident Physicians Threaten To Strike Over Low Wages
Event
subject: 'Evil genius' may have caused Terra and Luna cryptocurrencies to crash in a 'death spiral'
Event
subject: An off-duty officer put his knee on a 12-year-old girl's neck to break up a school fight. The girl is now being charged
Event
subject: 'Unthinkable tragedy': U.S. COVID-19 death toll surpasses 1 million
Event
subject: Twitter fires two executives, adding to Elon Musk buyout turmoil
Event
subject: North Korea confirms first COVID death; 350,000 reporting 'fever'
Event
subject: 'Holy cow ... are you kidding me?' Scientists stunned to see plants grow in soil from the moon
Event
body:

found


subject: Will r/mildlyinfuriating be able to reach 4.2M subscribers on May 16th 2022?
Event
body:

found


subject: How many upvotes will top post of the week on reddit will have on 15th May 2022?
Event
body:

found


subject: Which dessert will be more popular on 17th May 2022 ?
Event
body:

found


subject: Pick a random option !
Event
subject: r/mildlyinfuriating predictions tournament 1
Event
subject: San Jose police officer faces charges for masturbating during disturbance call: D.A.
Event
subject: Delaware AG asks for federal civil rights review after Del. State bus incident : NPR
Event
subject: US secretly issued subpoena to access Guardian reporter's phone records
Event
subject: U.S. groups urge social media companies to fight 'Big Lie," election disinformation
Event
subject: U.S. licenses key Covid vaccine technology to WHO so other countries can develop shots
Event
subject: City of Ferris will offer free healthcare to all its residents
Event
body:

WHO's COVID-19 Technology Access Pool (C-TAP) and the Medicines Patent Pool (MPP) today finalized a licensing agreement with the United States National Institutes of Health (NIH) for the development of several innovative therapeutics, early-stage vaccines and diagnostic tools for COVID-19.

The licenses, which are transparent, global and non-exclusive, will allow manufacturers from around the world to work with MPP and C-TAP to make these technologies accessible to people living in low- and middle-income countries and help put an end to the pandemic.

The 11 COVID-19 technologies offered under two licences include the stabilized spike protein used in currently available COVID-19 vaccines, research tools for vaccine, therapeutic and diagnostic development as well as early-stage vaccine candidates and diagnostics. The full list of the NIH COVID-19 technologies covered in the agreement is here.

"I welcome the generous contribution NIH has made to C-TAP and its example of solidarity and sharing," said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. "Whether it's today's pandemic or tomorrow's health emergency, it's through sharing and empowering lower-income countries to manufacture their own health tools that we can ensure a healthier future for everyone."

"We are honoured to sign these public health-driven licence agreements with NIH under the auspices of C-TAP with the goal of providing equitable access to life-saving health products for the most vulnerable in the world," said Charles Gore, MPP Executive Director.

"NIH were the first to share their patents with MPP for an HIV product back in 2010 when we were created, and we are delighted to continue strengthening our partnership. It is clear that MPP's model works across different health technologies."

The announcement was made today by the US Government at the second Global COVID-19 Summit, co-hosted by the United States, Belize, Germany, Indonesia and Senegal.

Licensing the NIH technologies to MPP under the auspices of C-TAP will allow greater access to these technologies and hopefully lead to the development of commercial products that can address current and future public health needs. In most circumstances, NIH will not collect royalties on sales of products licensed in 49 countries classified by the United Nations as Least Developed Countries.

Launched in 2020 by the WHO Director-General and the President of Costa Rica, and supported by 43 Member States, C-TAP aims to facilitate timely, equitable and affordable access to COVID-19 health products by boosting their production and supply through open, transparent and non-exclusive licensing agreements. MPP provides the licensing expertise to this initiative and holds the licences.

The 11 technologies include: 

  1. Prefusion spike proteins  (Vaccine Development) 
  2. Structure-Based Design of Spike Immunogens  (Research Tool for Vaccine Development) 
  3. Pseudotyping Plasmid (Research Tool for Vaccine Development) 
  4. ACE2 Dimer construct (Research Tool for Drug Development) 
  5. Synthetic humanized llama nanobody library and related use  (Research Tool for Drug and Diagnostic Development)
  6. Newcastle Disease Virus-Like Particles Displaying Prefusion-Stabilized  Spikes (Vaccine Candidate) 
  7. Parainfluenza virus 3 based vaccine (Vaccine Candidate)
  8. A VSV-EBOV-Based Vaccine (Vaccine Candidate)
  9. RNASEH-Assisted Detection Assay for RNA (Diagnostic)
  10. Detection of SARS-CoV-2 and other RNA Virus (Diagnostic)
  11. High-Throughput Diagnostic Test  (Diagnostic)

 



WHO's COVID-19 Technology Access Pool (C-TAP) and the Medicines Patent Pool (MPP) today finalized a licensing agreement with the United States National Institutes of Health (NIH) for the development of several innovative therapeutics, early-stage vaccines and diagnostic tools for COVID-19.

The licenses, which are transparent, global and non-exclusive, will allow manufacturers from around the world to work with MPP and C-TAP to make these technologies accessible to people living in low- and middle-income countries and help put an end to the pandemic.

The 11 COVID-19 technologies offered under two licences include the stabilized spike protein used in currently available COVID-19 vaccines, research tools for vaccine, therapeutic and diagnostic development as well as early-stage vaccine candidates and diagnostics. The full list of the NIH COVID-19 technologies covered in the agreement is here.

"I welcome the generous contribution NIH has made to C-TAP and its example of solidarity and sharing," said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. "Whether it's today's pandemic or tomorrow's health emergency, it's through sharing and empowering lower-income countries to manufacture their own health tools that we can ensure a healthier future for everyone."

"We are honoured to sign these public health-driven licence agreements with NIH under the auspices of C-TAP with the goal of providing equitable access to life-saving health products for the most vulnerable in the world," said Charles Gore, MPP Executive Director.

"NIH were the first to share their patents with MPP for an HIV product back in 2010 when we were created, and we are delighted to continue strengthening our partnership. It is clear that MPP's model works across different health technologies."

The announcement was made today by the US Government at the second Global COVID-19 Summit, co-hosted by the United States, Belize, Germany, Indonesia and Senegal.

Licensing the NIH technologies to MPP under the auspices of C-TAP will allow greater access to these technologies and hopefully lead to the development of commercial products that can address current and future public health needs. In most circumstances, NIH will not collect royalties on sales of products licensed in 49 countries classified by the United Nations as Least Developed Countries.

Launched in 2020 by the WHO Director-General and the President of Costa Rica, and supported by 43 Member States, C-TAP aims to facilitate timely, equitable and affordable access to COVID-19 health products by boosting their production and supply through open, transparent and non-exclusive licensing agreements. MPP provides the licensing expertise to this initiative and holds the licences.

The 11 technologies include: 

  1. Prefusion spike proteins  (Vaccine Development) 
  2. Structure-Based Design of Spike Immunogens  (Research Tool for Vaccine Development) 
  3. Pseudotyping Plasmid (Research Tool for Vaccine Development) 
  4. ACE2 Dimer construct (Research Tool for Drug Development) 
  5. Synthetic humanized llama nanobody library and related use  (Research Tool for Drug and Diagnostic Development)
  6. Newcastle Disease Virus-Like Particles Displaying Prefusion-Stabilized  Spikes (Vaccine Candidate) 
  7. Parainfluenza virus 3 based vaccine (Vaccine Candidate)
  8. A VSV-EBOV-Based Vaccine (Vaccine Candidate)
  9. RNASEH-Assisted Detection Assay for RNA (Diagnostic)
  10. Detection of SARS-CoV-2 and other RNA Virus (Diagnostic)
  11. High-Throughput Diagnostic Test  (Diagnostic)

 

subject: WHO and MPP announce agreement with NIH for COVID-19 health technologies
Event
subject: Coronavirus committee: Meat companies lied about impending shortage and put workers at risk
Event
subject: Coronavirus 'ghosts' found lingering in the gut
Event
subject: North Korea faces its first covid outbreak without any vaccines
Event
subject: 4 questions about long Covid experts wish they could answer [Vox article]
Event
subject: Is Paxlovid, the Covid Pill, Reaching Those Who Most Need It? The Government Won't Say
Event
subject: Family of Abducted Girl Claims Inaction of Dallas Police & Mavs in Sex Trafficking Case
Event
subject: 2 arrested after 1 killed, 16 hurt at outdoor Dallas concert
Event
subject: Black hole: First picture of Milky Way monster
Event
subject: Italy Will Not Abolish Face Mask Requirement on Flights Until June 15, Despite EU Recommendation
Event
subject: This is how many lives could have been saved with COVID vaccinations in each state
Event
subject: North Korea announces first Covid deaths amid 'explosive' outbreak
Event
subject: North Korea reports first COVID-19 death after 350,000 reported fevers
Event
subject: US oil refineries spewing cancer-causing benzene into communities, report finds
Event
subject: 'Like an inferno:' US West burning at furious pace so far
Event
subject: Was North Korea's military parade a superspreader event?
Event
subject: Taiwan reports 65,011 new COVID-19 cases, 41 deaths
Event
subject: Israeli police beat mourners with batons at funeral procession for veteran journalist
Event
subject: 'Amelia Baca was executed:' Baca family, attorneys demand murder charge in police killing
Event
subject: Scientists grow plants in lunar dirt, next stop moon
Event
subject: Users in Texas, Illinois can no longer use certain filters on Instagram and Facebook
Event
subject: S. Korea's new COVID-19 cases below 40,000s for 2nd day
Event
subject: Massachusetts to Pay $56 Million After Deadly Covid Outbreak at Veterans' Home
Event
subject: Calling a man bald counts as sexual harassment, UK judge rules
Event
subject: Air Force crew disciplined for landing on Martha's Vineyard to pick up vintage BMW motorcycle
Event
subject: Denver Broncos WR Jerry Jeudy arrested, faces charge of criminal tampering with domestic violence enhancer
Event
subject: N.J. teacher's aide charged after he's accused of 'viciously' assaulting 7-year-old student with autism
Event
subject: Federal operation nabs nearly 43,000 illegal gun silencers shipped from China
Event
subject: Patients charged hundreds of dollars to get Covid drugs already paid for by taxpayers
Event
subject: Texas Supreme Court allows state to resume some abuse investigations into gender-confirming care for transgender youth
Event
subject: First Russian soldier goes on trial in Ukraine for war crimes
Event
subject: 13,598 COVID-19 deaths in Georgia could have been prevented by vaccine, new study suggests
Event
subject: The U.S. Is About to Make a Big Gamble on Our Next COVID Winter
Event
subject: 'Not free from COVID': Thousands pray at Portuguese shrine despite fears of new wave
Event
subject: Mom suing TikTok after 10-year-old daughter dies from dangerous "Blackout Challenge"
Event
subject: Thousands mourn slain journalist as Palestinians call for accountability

Comments

Post a Comment